文献简介

出版社:

作  者:

编  号:

关键字:黑色素瘤;靶向治疗

年  份:2020   点击量:20

文献摘要 全文翻译

Over the past decade, there has been significant advancement in the understanding of the pathophysiology of melanoma. These advancements have led to the systematic development of new effective therapies for advanced disease in the form of molecularly targeted therapy and immunotherapy. Randomized trials have also demonstrated efficacy in reducing relapse after complete surgical resection of stage III or stage IV melanoma, thus making modern management of melanoma a multidisciplinary endeavor. The most common activating mutations in melanoma cells are BRAF, NRAS, and KIT mutations. These mutations cause derangements in cell signaling pathways, leading to unchecked tumor proliferation. The cell signaling pathways implicated in the progression of benign melanocytes to malignant disease are now better understood. These pathways may be the key to identifying new therapeutic targets and providing more options against this devastating disease.

过去十年,在黑色素瘤的病理生理学的理解上取得了重大进展。这些进展导致了晚期疾病分子靶向治疗和免疫新疗法的系统发展。随机试验也表明,其在III期或IV期黑色素瘤完全手术切除后,减少复发的有效性,从而促使多学科联合管理黑色素瘤。黑色素瘤细胞中最常见的激活突变是BRAFNRASKIT突变。这些突变导致细胞信号通路紊乱,导致肿瘤不受抑制增殖。现在已经更好地理解了良性黑素细胞发展为恶性疾病有关的细胞信号通路。这些途径可能是确定新的治疗靶点的关键,并为对抗这类严重疾病提供更多的治疗选择。